Netupitant/Palonosetron Hydrochloride

HONG KONG, Nov. 6, 2025 /PRNewswire/ -- On 5 November 2025, the 8th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center (Shanghai). As a "full-attendance" exhibitor for eight consecutive years, Fosun, together with its overseas member companies and global partners, is showcasing a range of world-leading innovative drugs, advanced medical devices, and achievements in international collaboration at the Fosun Pharma booth in the Medical Equipment and Healthcare Products Exhibition Area. The exhibits focus on core therapeutic areas including oncology, immune-inflammatory disorders, central nervous system, and kidney diseases, highlighting holistic breakthroughs in medical technology, from diagnosis and treatment to recovery. Guo Guangchang, Chairman of Fosun International, remarked, "Over the past eight years, the CIIE has continued to grow in influence and innovate, serving as a key window into China's new development paradigm, a platform for advancing high-level opening-up, and a global public good that benefits the international community. We have witnessed and benefited from this 'everlasting' showcase. The CIIE has enabled Fosun's global innovations to continuously transform from 'exhibits' into 'products', while many overseas partners have changed their roles from 'exhibitors' to 'investors'. Fosun believes that healthcare innovation should address unmet clinical needs and bring hope of cure to patients. This year, our showcases in the Medical Equipment and Healthcare Products Exhibition Area center on the latest advancements addressing global clinical needs, with several new products making their debut. We firmly believe that China's high-level opening-up will remain a source of certainty and opportunity for global development. Looking ahead, Fosun will further capitalize on its global industrial advantages to foster more cutting-edge innovations in China, contributing the 'power of Fosun' to fulfill people's aspirations for a better life." Focusing on oncology: advancing from "treatment" to "cure" Fosun is presenting a series of cutting-edge innovative products aimed at advancing oncology from "treatment" to "cure" at this year's CIIE. Among them, the debut product, the Marie Upright Particle Therapy System, has attracted significant attention. As a revolutionary breakthrough in cancer treatment, the Marie Upright Particle Therapy System eliminates the cumbersome structure of conventional particle therapy system, enabling rapid deployment within existing medical facilities. Studies show that the upright positioning enhances precision in tumors located in the lung, breast, abdomen, and other areas. The system supports multiple advanced particle therapy modalities including proton therapy, heavy ion therapy, boron neutron capture therapy (BNCT), and FLASH radiotherapy, offering patients more precise, comfortable, and flexible treatment options. The Marie Upright Particle Therapy System, which received U.S. Food and Drug Administration (FDA) approval in July 2025, is making its debut in China at this year's CIIE. In the field of hematologic oncology, Fosun's Yi Kai Da (ejilunsai injection), China's first CAR-T cell therapy product, continues to share the latest developments in making lymphoma treatment both accessible and curative at the CIIE. This year, Yi Kai Da has made multiple major advances: inclusion in over 110 urban customized commercial health insurances and over 80 commercial insurances; establishment of over 190 high-standard treatment centers across 29 provinces and cities nationwide, benefiting more than 1,000 lymphoma patients; successful first-ever cross-border shipping and usage in Hong Kong SAR and Macau SAR; and a remarkable case of the first patient treated with Yi Kai Da in the Chinese mainland achieving over seven years of high-quality survival. Notably, following Yi Kai Da, the drug registration application of Fosun's second CAR-T product, brexucabtagene autoleucel injection, was accepted by the National Medical Products Administration (NMPA) in September 2025. The declared indication for this application is for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Regarding supportive care in cancer, Fosun is showcasing several innovative drugs that fill treatment gaps in the domestic market. These include the world's first and currently only dual-channel antiemetic, Akynzeo (netupitant and palonosetron hydrochloride capsules); China's first oral thrombopoietin receptor agonist with dual indications for chronic liver disease-associated thrombocytopenia and immune thrombocytopenia, Su Ke Xin (avatrombopag maleate tablets); and the long-acting recombinant human granulocyte colony-stimulating factor, Pei Jin (telpegfilgrastim injection). Additionally, Wan Ti Le (tenapanor hydrochloride tablets), a "CIIE baby" introduced to China through the CIIE, received approval from the NMPA in February 2025. It is indicated for the control of serum phosphorus levels in dialysis patients with chronic kidney disease. This groundbreaking innovation has also been shortlisted as a candidate for Best Pharmaceutical Product at the Prix Galien 2025. Addressing neurological disorders with innovative drugs and devices In recent years, the number of patients with neurological disorders has rapidly increased, with a notable trend toward younger patients. Disorders such as Parkinson's disease, brain tumors, and epilepsy have attracted growing attention. Focusing on unmet clinical needs, Fosun is actively exploring world-leading innovative solutions. In advanced medical devices, Fosun is once again featuring cutting-edge non-invasive treatments, the magnetic resonance image guided focused ultrasound brain therapy system (MRgFUS brain therapy system) and the world's first 128-channel helium-free Marvel magnetoencephalography (MEG), at the CIIE, providing integrated solutions from precise localization to non-invasive treatment for common neurological disorders such as Parkinson's disease, brain tumors, and epilepsy. To date, more than 25,000 patients worldwide have benefited from the MRgFUS brain therapy system. Its new V2 model, featuring enhanced device compatibility and easier operation, has obtained CE marking in the European Union and U.S. FDA approval. Since its debut at the last CIIE, the MRgFUS brain therapy system has been deployed in over 10 medical institutions in the Chinese mainland, benefiting nearly 1,000 patients. In the field of innovative drugs, Fosun has introduced a world-leading combination therapy for Parkinson's disease, contributing to the continuous improvement of diagnosis and treatment in China. The oral COMT inhibitor, Ongentys (opicapone) is currently the only once-daily COMT inhibitor approved globally, offering convenient dosing that significantly enhances treatment adherence and long-term disease management. Ongentys is already in clinical use in pilot zones such as Boao Lecheng, leveraging special access policies for clinical prescriptions and paving the way for broader national adoption. Integrating global resources to drive local innovation, embracing AI to accelerate breakthroughs Fosun continues to integrate global resources to advance cutting-edge medical technologies in China. Leveraging CIIE's support in transforming "exhibits" into "products", Intuitive Fosun's surgical system has been gradually launched, contributing to the development of a high-quality healthcare system in China. The Da Vinci surgical system, a popular exhibit at the CIIE for eight consecutive years, has witnessed the rapid development of minimally invasive surgery in China. By the end of September 2025, over 480 Da Vinci surgical systems had been installed in more than 370 hospitals across the Chinese mainland, Hong Kong SAR, and Macau SAR, collectively serving over 810,000 patients. This year, Intuitive Fosun is showcasing several surgical systems, including the domestically produced multiport Da Vinci Xi surgical system, the single-port Da Vinci SP surgical system designed for single-incision or natural orifice surgeries, and the Ion Robotic Bronchoscopy that brings breakthrough innovations in lung cancer diagnosis and treatment. To better meet China's clinical needs, Intuitive Fosun Innovation Center has partnered with over 20 grade 3A hospitals accredited by the National Health Commission of the People's Republic of China to establish Da Vinci Surgical System Training Centers, creating an integrated training system that combines clinical practice with education. To date, Intuitive Fosun has established 7 regional training centers across China and trained more than 15,000 medical professionals, promoting the standardized and sustainable development of surgical systems nationwide. In digital transformation, Fosun actively embraces AI and has gradually built a comprehensive digital and intelligent system covering research and development, operations, and product applications. At this year's CIIE, Fosun Pharma is showcasing its PharmAID decision intelligence platform, which deeply integrates leading large model technologies such as DeepSeek, achieving intelligent leaps in drug commercial decision-making, clinical trial prediction, and toxicology optimization. In medical aesthetics, Sisram is presenting revolutionary solutions including Alma IQ, an intelligent skin analysis and consultation solution, and Universkin, the world's first AI-assisted medical-grade skincare line launched in North America, setting new standards for personalized treatment. In healthcare services, Fosun Health continues to explore deep AI applications in assisted diagnosis, treatment quality control, and proactive health management. Leveraging four core hospitals in the Greater Bay Area including Foshan Fosun Chancheng Hospital, Fosun Health has established an internationalized service platform integrating online and offline resources, providing one-stop services from remote consultation to full patient care for individuals from Japan, Bangladesh, Indonesia, Peru, and other countries. Guo Guangchang said, "Looking ahead, Fosun will leverage its long-established innovation and globalization capabilities, collaborating with global partners to continuously drive high-quality development of the pharmaceutical industry and help realize the ambitious vision of 'Healthy China 2030'." SOURCE Fosun 21% more press release views with Request a Demo

AKYNZEO® demonstrates superior prevention of chemotherapy-induced nausea and vomiting compared to the standard of care in patients receiving moderately emetogenic chemotherapy with additional predictive factors Results from the MyRisk clinical trial, accepted for publication in the Annals of Oncology, will be presented today at ESMO 2025 as an oral presentation Lugano, Switzerland, October 17, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of nearly fifty years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, today announces that results from the MyRisk Trial with AKYNZEO®, a fixed antiemetic combination of netupitant and palonosetron, will be featured as an oral presentation at the European Society for Medical Oncology (ESMO) Congress today, on October 17, 2025. The complete trial results have also been accepted for publication in the Annals of Oncology, underscoring their significance in advancing supportive care for patients receiving moderately emetogenic chemotherapy (MEC). Patients receiving MEC are typically prescribed a 5-HT3 receptor antagonist (RA) and dexamethasone (DEX) as standard antiemetic prophylaxis. However, some patients with additional risk factors for chemotherapy-induced nausea and vomiting (CINV) may benefit from enhanced antiemetic prophylaxis with an NK1 RA–containing regimen. The MyRisk trial was a Phase IV, interventional, open-label, randomized, multicenter, multinational trial conducted in seven countries. It is the first trial to prospectively incorporate a predictive risk factor algorithm to select patients at increased risk of CINV receiving MEC. The primary objective was to evaluate whether the use of AKYNZEO® + DEX was more effective than guideline-recommended standard of care (SOC; 5-HT3 RA + DEX) across three consecutive cycles. A total of 388 patients were included in the analysis. The primary endpoint was met; patients receiving AKYNZEO® were significantly more likely to achieve a complete response (CR: no emesis and no use of rescue medication) than those in the SOC arm in the overall phase (0-120 h after chemotherapy), with 67% greater odds (OR = 1.67, 95% CI: 1.12, 2.49). The statistical model estimated the probability of CR in the AKYNZEO® arm was 81.0% versus 71.8% in the SOC arm. This superiority was consistently observed across several secondary efficacy endpoints including “no nausea”, typically the most challenging symptom to control. Prof. Alex Molasiotis, University of Derby, Derby, United Kingdom, the lead author of the study, commented: “These results reinforce that standard doublet therapy may be insufficient for many patients, with the MyRisk trial highlighting the benefit of AKYNZEO®-based prophylaxis in individuals receiving moderately emetogenic chemotherapies. Importantly, initiating optimal prophylaxis from the first chemotherapy cycle is crucial, as CINV becomes significantly more difficult to control once experienced by patients, underscoring the need for proactive and tailored antiemetic strategies from the outset.” Silvia Olivari, Helsinn Group, Head of Medical Strategy & Excellence, added: “Patients receiving MEC represent a large part of the chemotherapy population and are often underserved by current standards. Tailoring antiemetic prophylaxis to individual patient characteristics can significantly enhance the prevention of CINV, with a particular benefit in controlling nausea, a persistent and often underestimated unmet need in supportive cancer care. We’re also proud of the recognition by ESMO and Annals of Oncology.” The details of the ESMO presentation are as follows: Title: Personalizing Antiemetic Prophylaxis for Patients at High Emetic Risk: Results from the MyRisk Trial Authors: Alex Molasiotis (Derby, United Kingdom), Karin Jordan (Potsdam, Germany), Meinolf Karthaus (Munich, Germany), George Dranitsaris (Toronto, Canada), Eric J. Roeland (Portland, United States of America), Lee S. Schwartzberg (Reno, United States of America), Erminio Bonizzoni (Milan, Italy), Elena Brozos Vazquez (A Coruña, Spain), Tomas Buchler (Prague, Czech Republic), Yu Cheng (Shanghai, China), Daniel C. Christoph (Herne, Germany), Pilar García Alfonso (Madrid, Spain), Xin Lu (Shanghai, China), Margarita Majem (Barcelona, Spain), Dimitrios Mavroudis (Heraklion, Greece), Konstantinos Syrigos (Athens, Greece), Elaine Tomlins (London, United Kingdom), Zhen Zhou (Shanghai, China), Martina Zimovjanova (Prague, Czech Republic), Matti S. Aapro (Genolier, Switzerland)Presentation number: 2801OSession title: Supportive and palliative careDate, time and location: Friday, October 17th, 16:00 – 17:30, Hanover Auditorium, Hall 7.2c ESMO 2025 will be held from 17-21 October 2025 in Berlin, Germany. Further details can be found here: ESMO Congress 2025 | ESMO About AKYNZEO® (NEPA: netupitant/palonosetron) AKYNZEO® is the first and only 5-HT3 and NK1 receptor antagonist fixed antiemetic combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy. For additional information, please see the EU Summary of Product Characteristics. About the Helsinn Group Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic diseases, with a focus on supportive care, oncology, and dermato-oncology. Headquartered in Lugano, Switzerland, Helsinn has direct commercial operations in the U.S., manufacturing operations in Ireland, offices in China and a network of trusted partners enabling a commercial presence in 90 countries. Established in 1976, Helsinn is a fourth-generation family-owned company with broad pharmaceutical and technical expertise. For nearly half a century, Helsinn has been operating with integrity, passion, and quality. The company continuously strives for innovation for its patients and embraces sustainable growth as a core element of its strategic vision.To learn more about Helsinn, please visit www.helsinn.com or follow us on LinkedIn and x.